The report "Global Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and Region - Global Forecast to 2029" Global Duchenne Muscular Dystrophy Treatment market is projected to grow from US $xx billion in 2019 to US$ XX billion by 2029. The rising burden of Duchenne muscular dystrophy (DMD) disease is the major factor driving the growth for the target market. The increasing prevalence of chronic diseases, such as cardiovascular and neurovascular diseases, and arthritis are the major factor boosting the growth for the target market. However, factor such as changing government regulations and norms restrain market growth.
Key Highlights:
- In April 2019 FibroGen a leading biopharmaceutical company receives orphan drug designation from the U.S. FDA for pamrevlumab for the treatment of Duchenne muscular dystrophy.
Key Market Insights from the report:
The global Duchenne Muscular Dystrophy Treatment market accounted for US$ XX billion in 2019 and is projected to register a moderate CAGR of XX% over the forecast period. The market report has been segmented on the basis, By Therapeutic Approach and Treatment Type, End-User, and by a region.
- By Therapeutic Approach and Treatment Type global Duchenne Muscular Dystrophy Treatment market is classified into molecular-based therapies (mutation suppression, and exon skipping), steroid therapy (corticosteroids), nonsteroidal anti-inflammatory drugs (NSAIDs) and other therapeutic approaches and treatment end users.
- By End-User global Duchenne Muscular Dystrophy Treatment, the market is classified into hospitals/clinics, ambulatory centres, and other end users.
- By region, The Asia Pacific market is expected to show the highest CAGR owing to growing awareness about Duchenne muscular dystrophy and growing public and private health care insurance coverage. North America is expected to domination the market. Owing to product innovations, great healthcare expenditure, and support of government awareness programs.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - forecast till 2029
To know the upcoming trends and insights prevalent in this market, click the link below:
Links: https://prophecymarketinsights.com/market_insight/Global-Duchenne-Muscular-Dystrophy-Treatment-3969
The key players operating the global Duchenne Muscular Dystrophy Treatment market include BioMarin, Bristol-Myers Squibb Company, Fibrogen Inc., Eli Lilly and Company, Nobelpharma Co. Ltd, NS Pharma Inc., Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics. The Key players in the market are focusing on mutual understanding.
About Prophecy Market Insights
Prophecy Market Insights is a specialized market research, analytics, marketing and business strategy, and solutions company that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. Also, we help our client to address business challenges and provide the best possible solutions to overcome them and transform their business.
Contact Us:
Sales
Prophecy Market Insights
Email- This email address is being protected from spambots. You need JavaScript enabled to view it.